- call +1-201-465-4211
- email sales@mrinsights.biz
Gene therapy is a technique for correcting defective genes responsible for disease development. Nucleic acid-based molecules (deoxyribonucleic acid, complementary deoxyribonucleic acid, complete genes, ribonucleic acid, and oligonucleotides) are utilized as research tools within the broad borders of gene therapy and the emerging field of molecular medicine.
Scope of the Report:
This report studies the Nucleic Acid-based Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Nucleic Acid-based Therapeutics market by product type and applications/end industries.
Although most of the nucleic acid-based drugs are in early stages of clinical trials, these classes of compounds have emerged in recent years to yield extremely promising candidates for drug therapy to a wide range of diseases, including cancer, infectious diseases, diabetes, cardiovascular, inflammatory, and neurodegenerative diseases, cystic fibrosis, hemophilia, and other genetic disorders.
The global Nucleic Acid-based Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Nucleic Acid-based Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Wave Life Sciences
Imugene
Caperna
Phylogica
Protagonist Therapeutics
Benitec Biopharma
EGEN
BioMedica
Transgene
Copernicus Therapeutics
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Anti-Sense And Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Market Segment by Applications, can be divided into
Monogenetic Disorders
Multi-Genetic Disorders
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Nucleic Acid-based Therapeutics Market Overview
1.1 Product Overview and Scope of Nucleic Acid-based Therapeutics
1.2 Classification of Nucleic Acid-based Therapeutics by Types
1.2.1 Global Nucleic Acid-based Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Nucleic Acid-based Therapeutics Revenue Market Share by Types in 2017
1.2.3 Anti-Sense And Anti-Gene
1.2.4 Short Inhibitory Sequences
1.2.5 Gene Transfer Therapy
1.2.6 Nucleoside Analogs
1.2.7 Ribozymes
1.2.8 Aptamers
1.3 Global Nucleic Acid-based Therapeutics Market by Application
1.3.1 Global Nucleic Acid-based Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Monogenetic Disorders
1.3.3 Multi-Genetic Disorders
1.4 Global Nucleic Acid-based Therapeutics Market by Regions
1.4.1 Global Nucleic Acid-based Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Nucleic Acid-based Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Nucleic Acid-based Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Nucleic Acid-based Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Nucleic Acid-based Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Nucleic Acid-based Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Nucleic Acid-based Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Wave Life Sciences
2.1.1 Business Overview
2.1.2 Nucleic Acid-based Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Wave Life Sciences Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Imugene
2.2.1 Business Overview
2.2.2 Nucleic Acid-based Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Imugene Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Caperna
2.3.1 Business Overview
2.3.2 Nucleic Acid-based Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Caperna Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Phylogica
2.4.1 Business Overview
2.4.2 Nucleic Acid-based Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Phylogica Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Protagonist Therapeutics
2.5.1 Business Overview
2.5.2 Nucleic Acid-based Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Protagonist Therapeutics Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Benitec Biopharma
2.6.1 Business Overview
2.6.2 Nucleic Acid-based Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Benitec Biopharma Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 EGEN
2.7.1 Business Overview
2.7.2 Nucleic Acid-based Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 EGEN Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 BioMedica
2.8.1 Business Overview
2.8.2 Nucleic Acid-based Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 BioMedica Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Transgene
2.9.1 Business Overview
2.9.2 Nucleic Acid-based Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Transgene Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Copernicus Therapeutics
2.10.1 Business Overview
2.10.2 Nucleic Acid-based Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Copernicus Therapeutics Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Nucleic Acid-based Therapeutics Market Competition, by Players
3.1 Global Nucleic Acid-based Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Nucleic Acid-based Therapeutics Players Market Share
3.2.2 Top 10 Nucleic Acid-based Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Nucleic Acid-based Therapeutics Market Size by Regions
4.1 Global Nucleic Acid-based Therapeutics Revenue and Market Share by Regions
4.2 North America Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Nucleic Acid-based Therapeutics Revenue by Countries
5.1 North America Nucleic Acid-based Therapeutics Revenue by Countries (2013-2018)
5.2 USA Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Nucleic Acid-based Therapeutics Revenue by Countries
6.1 Europe Nucleic Acid-based Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Nucleic Acid-based Therapeutics Revenue by Countries
7.1 Asia-Pacific Nucleic Acid-based Therapeutics Revenue by Countries (2013-2018)
7.2 China Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Nucleic Acid-based Therapeutics Revenue by Countries
8.1 South America Nucleic Acid-based Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Nucleic Acid-based Therapeutics by Countries
9.1 Middle East and Africa Nucleic Acid-based Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Nucleic Acid-based Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Nucleic Acid-based Therapeutics Market Segment by Type
10.1 Global Nucleic Acid-based Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Nucleic Acid-based Therapeutics Market Forecast by Type (2018-2023)
10.3 Anti-Sense And Anti-Gene Revenue Growth Rate (2013-2023)
10.4 Short Inhibitory Sequences Revenue Growth Rate (2013-2023)
10.5 Gene Transfer Therapy Revenue Growth Rate (2013-2023)
10.6 Nucleoside Analogs Revenue Growth Rate (2013-2023)
10.7 Ribozymes Revenue Growth Rate (2013-2023)
10.8 Aptamers Revenue Growth Rate (2013-2023)
11 Global Nucleic Acid-based Therapeutics Market Segment by Application
11.1 Global Nucleic Acid-based Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Nucleic Acid-based Therapeutics Market Forecast by Application (2018-2023)
11.3 Monogenetic Disorders Revenue Growth (2013-2018)
11.4 Multi-Genetic Disorders Revenue Growth (2013-2018)
12 Global Nucleic Acid-based Therapeutics Market Size Forecast (2018-2023)
12.1 Global Nucleic Acid-based Therapeutics Market Size Forecast (2018-2023)
12.2 Global Nucleic Acid-based Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Nucleic Acid-based Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Nucleic Acid-based Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Nucleic Acid-based Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Nucleic Acid-based Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Nucleic Acid-based Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Nucleic Acid-based Therapeutics Picture
Table Product Specifications of Nucleic Acid-based Therapeutics
Table Global Nucleic Acid-based Therapeutics and Revenue (Mil
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
